Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Other Operating Expenses (2016 - 2026)

Cytosorbents filings provide 15 years of Other Operating Expenses readings, the most recent being $22.5 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 691.04% to $22.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.5 million, a 123.65% increase, with the full-year FY2025 number at $2.1 million, up 109.11% from a year prior.
  • Other Operating Expenses hit $22.5 million in Q4 2025 for Cytosorbents, up from -$6.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $22.5 million in Q4 2025 to a low of -$6.9 million in Q1 2024.
  • Median Other Operating Expenses over the past 5 years was $625361.5 (2021), compared with a mean of -$614405.4.
  • Biggest five-year swings in Other Operating Expenses: crashed 1276.29% in 2024 and later soared 691.04% in 2025.
  • Cytosorbents' Other Operating Expenses stood at $641205.0 in 2021, then grew by 18.3% to $758569.0 in 2022, then crashed by 548.51% to -$3.4 million in 2023, then decreased by 12.07% to -$3.8 million in 2024, then soared by 691.04% to $22.5 million in 2025.
  • The last three reported values for Other Operating Expenses were $22.5 million (Q4 2025), -$6.0 million (Q3 2025), and -$5.8 million (Q2 2025) per Business Quant data.